Journal Scans
Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
Complete Response Can Happen With TKIs in Renal Cell Carcinoma
L Albiges, S Oudard, S Negrier, A Caty, G Gravis, F Joly, B Duclos, L Geoffrois, F Rolland, A Guillot, B Laguerre, E Legouffe, F Kohser, P-Y Dietrich, CA Theodore, B Escudier
20120009
2012 Jan 9
J Clin Oncol
Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma
J Clin Oncol. 2012 Jan 9;[Epub Ahead of Print], L Albiges, S Oudard, S Negrier, A Caty, G Gravis, F Joly, B Duclos, L Geoffrois, F Rolland, A Guillot, B Laguerre, E Legouffe, F Kohser, P-Y Dietrich, CA Theodore, B Escudier
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Tyrosine kinase inhibitors (TKIs) like sunitinib and sorafenib have revolutionized the treatment of metastatic renal cell carcinoma (mRCC), defining a new “post-cytokine” era of therapy. Patients receiving these multi-target TKIs can, rarely, achieve complete response (CR) on serial radiographs. This retrospective analysis solicited medical oncologists at 15 French or Swiss centers to submit cases of CR in mRCC treated with sunitinib or sorafenib between 2005 and 2009. Dosing of each TKI was standard,...
